Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring Life Science Investing
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia Life Science Investing
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients Biotech Investing
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 Life Science Investing
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 Life Science Investing
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata Life Science Investing
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy Life Science Investing
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy Life Science Investing
Innovotech Inc. Announces Intention to Apply for Trading on the OTCQB Venture Market Life Science Investing
